Monopar Therapeutics Inc. $MNPR Shares Acquired by Ally Bridge Group NY LLC

Ally Bridge Group NY LLC increased its position in shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) by 86.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 64,455 shares of the company’s stock after purchasing an additional 29,918 shares during the period. Monopar Therapeutics makes up approximately 3.2% of Ally Bridge Group NY LLC’s portfolio, making the stock its 12th largest position. Ally Bridge Group NY LLC owned about 0.96% of Monopar Therapeutics worth $5,264,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the business. Wellington Management Group LLP acquired a new position in Monopar Therapeutics during the 3rd quarter worth approximately $18,904,000. Vanguard Group Inc. raised its stake in shares of Monopar Therapeutics by 140.7% during the 3rd quarter. Vanguard Group Inc. now owns 208,218 shares of the company’s stock worth $17,005,000 after buying an additional 121,729 shares in the last quarter. Deerfield Management Company L.P. acquired a new stake in shares of Monopar Therapeutics in the 3rd quarter valued at approximately $13,048,000. ADAR1 Capital Management LLC lifted its holdings in shares of Monopar Therapeutics by 28.7% in the 3rd quarter. ADAR1 Capital Management LLC now owns 129,999 shares of the company’s stock valued at $10,617,000 after buying an additional 29,025 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Monopar Therapeutics by 99.7% in the second quarter. Geode Capital Management LLC now owns 96,919 shares of the company’s stock valued at $3,468,000 after buying an additional 48,379 shares in the last quarter. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Thursday, January 22nd. Morgan Stanley initiated coverage on shares of Monopar Therapeutics in a research report on Friday, January 9th. They set an “overweight” rating and a $115.00 target price on the stock. BTIG Research reaffirmed a “buy” rating and set a $104.00 price target on shares of Monopar Therapeutics in a research note on Monday, February 23rd. Chardan Capital reiterated a “buy” rating and issued a $100.00 price target on shares of Monopar Therapeutics in a report on Thursday, January 29th. Finally, Wall Street Zen cut shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Monopar Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $107.00.

Insider Buying and Selling at Monopar Therapeutics

In other news, CFO Quan Anh Vu purchased 1,500 shares of the business’s stock in a transaction dated Friday, December 26th. The stock was acquired at an average price of $69.95 per share, with a total value of $104,925.00. Following the purchase, the chief financial officer directly owned 1,500 shares of the company’s stock, valued at $104,925. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 20.50% of the stock is currently owned by corporate insiders.

Monopar Therapeutics Stock Performance

Shares of MNPR stock opened at $60.36 on Friday. The stock has a fifty day moving average price of $61.30 and a 200 day moving average price of $69.41. The stock has a market cap of $403.39 million, a PE ratio of -17.55 and a beta of 1.58. Monopar Therapeutics Inc. has a 1 year low of $26.06 and a 1 year high of $105.00.

Monopar Therapeutics Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.